Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors

Human Pathology

Volumn 44, Issue 11, 2013, Pages 2427-2431

  Gulbahce, H Evin ^a   Sweeney, Carol ^a   Surowiecka, Maria ^b   Knapp, Dennis ^c   Varghese, Linda ^d   Blair, Cindy K ^e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VA MEDICAL CENTER   (United States)

^d FAIRVIEW SOUTHDALE HOSPITAL   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer; GATA 3; Outcomes

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR GATA 3;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; TISSUE MICROARRAY; TUMOR VOLUME;

BREAST CANCER; GATA-3; OUTCOMES;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GATA3 TRANSCRIPTION FACTOR; HUMANS; METHOTREXATE; MIDDLE AGED; MINNESOTA; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84885608202     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.05.022     Document Type: Article

References (13)

1. J. Eeckhoute, E.K. Keeton, M. Lupien, S.A. Krum, J.S. Carroll, and M. Brown Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer Cancer Res 67 2007 6477 6483
2. V. Ciocca, C. Daskalakis, R.M. Ciocca, A. Ruiz-Orrico, and J.P. Palazzo The significance of GATA3 expression in breast cancer: a 10-year follow-up study Hum Pathol 40 2009 489 495
3. M. Gonzalez, H. He, S. Sun, C. Li, and F. Li Cell cycle-dependent deposition of CENP-A requires the Dos1/2-Cdc20 complex Proc Natl Acad Sci U S A 110 2013 606 611
4. K. McCune, R. Mehta, M.A. Thorat, S. Badve, and H. Nakshatri Loss of ERalpha and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model Oncol Rep 24 2010 1233 1239
5. R.S. Gonzalez, J. Wang, T. Kraus, H. Sullivan, A.L. Adams, and C. Cohen GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance Hum Pathol 2012
6. Y. Chen, C. Chen, and B. Yang Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy Cancer Lett 302 2011 63 68
7. R. Mehra, S. Varambally, L. Ding, R. Shen, M.S. Sabel, and D. Ghosh Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis Cancer Res 65 2005 11259 11264
8. N. Tominaga, Y. Naoi, and K. Shimazu Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy Ann Oncol 2012
9. D. Voduc, M. Cheang, and T. Nielsen GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value Cancer Epidemiol Biomarkers Prev 17 2008 365 373
10. N.K. Yoon, E.L. Maresh, and D. Shen Higher levels of GATA3 predict better survival in women with breast cancer Hum Pathol 41 2010 1794 1801
11. H.E. Gulbahce, R. Gamez, L. Dvorak, C. Forster, and L. Varghese Concordance between tissue microarray and whole-section estrogen receptor expression and intratumoral heterogeneity Appl Immunohistochem Mol Morphol 20 2012 340 343
12. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43
13. F.O. Ademuyiwa, M.A. Thorat, R.K. Jain, H. Nakshatri, and S. Badve Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low oncotype DX 21-gene recurrence scores Mod Pathol 23 2010 270 275